J Korean Med Assoc Search

CLOSE


J Korean Med Assoc > Volume 46(6); 2003 > Article
Park and Lee: Molecular Targeted Therapy in Cancer

Abstract

Use of non-selective drugs to kill cancer cells means that healthy cells will inevitably be damaged and many patients will suffer severe side-effects. New therapies are continuously being sought to reduce the mortality from cancer. The targeted cancer therapy has been developed with advances in molecular biology and technology. Over the last several decades, a wealth of knowledge has emerged regarding the molecular events involved in human cancer. Understanding the molecular events in tumorigenesis and mechanism would provide knowledge in searching for novel targets. Through our understanding of signaling pathways regulating cellular growth, cell cycle, and apoptosis, numerous targets for anticancer agents have emerged. The targets usually include EGFR, transmembrane protein tyrosine kinase, protein kinase C, farnesyl transferase, angiogenesis, and metalloproteinase. It has become clear that targeted therapy is the important novel strategy for treatment of cancer through preclinical and clinical trials.

References

1. Herbst RS, Hong WK. Targeted therapy against the epidermal growth factor receptor. Semin Oncol 2002;29:1-69.

2. Savage DG, Antman KH. Imatinib mesylate-A new oral targeted therapy. N Engl J Med 2002;346:683-693.

3. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637-1647.

4. Herbst RS, Maddox AM. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors : results of a phase I trial. J Clin Oncol 2002;20(18):3815-3825.

5. Hidalgo M, Eckhardt SG. Development of martix metalloprotease inhibitors in cancer therapy. J Natl Cancer Inst 2001;93:178-193.

Figure 1
jkma-46-542-g001-l.jpg
Figure 2
jkma-46-542-g002-l.jpg
Figure 3
jkma-46-542-g003-l.jpg
Table 1
jkma-46-542-i001-l.jpg
Table 2
jkma-46-542-i002-l.jpg
Table 3
jkma-46-542-i003-l.jpg


ABOUT
ARTICLE CATEGORY

Browse all articles >

ARCHIVES
FOR CONTRIBUTORS
Editorial Office
37 Ichon-ro 46-gil, Yongsan-gu, Seoul
Tel: +82-2-6350-6562    Fax: +82-2-792-5208    E-mail: jkmamaster@gmail.com                

Copyright © 2024 by Korean Medical Association.

Developed in M2PI

Close layer
prev next